The prognostic role of survivin expression in breast cancer: A systematic review and meta-analysis

Betul Bolat Kucukzeybek,Yuksel Kucukzeybek,Yasemin Basbinar,Hulya Ellidokuz,Mustafa Agah Tekindal,Cigdem Dinckal,Mustafa Oktay Tarhan

DOI: https://doi.org/10.1097/md.0000000000040013

IF: 1.6

2024-10-09

Medicine

Abstract:Breast cancer ranks first in incidence among women and is a leading cause of cancer-related deaths. [ 1 ] It is a highly heterogeneous disease in terms of clinical and molecular characteristics, biological behavior, and response to treatments. Despite individualized surgical treatments, radiotherapy, and systemic therapies guided by gene expression panels or immunohistochemical subgroups, recurrence can occur, often leading to poor prognosis. [ 2 ] While widespread adjuvant systemic therapy has reduced breast cancer mortality rates in the Western world, many patients still do not receive appropriate treatment. Some patients receive systemic treatment when local treatment is sufficient, whereas others do not receive adequate or appropriate systemic therapy. Reliable prognostic factors that may help identify patients at the highest risk of recurrence and clinically usable predictive factors may help personalize treatment. All of these could potentially protect patients from exposure to any possible treatment toxicity. [ 3 ] Ozmen et al found that the median age at diagnosis of breast cancer was 51, and the majority of patients were at stage 2 at the time of diagnosis in Turkey. Histopathology was invasive ductal cancer in 77%. During the mean 51.6 months of follow-up, the local/regional and systemic recurrence rates were 3.7% and 5.2%, respectively; 5 and 10-year overall survival (OS) rates were 86% and 76%. [ 4 ]

medicine, general & internal